Enteral Nutrition in France
SKU:
$1,190.00
$1,190.00
per item
Around 40 percent of all hospital patients worldwide are malnourished. In France, around 2.7 mil. Patients have a BMI of less than 18.5 kg / m² - the trend is rising. The stationary market for enteral nutrition in France is stagnating due to the growing importance of the French homecare sector, which is growing in the medium single-digit percentage range.
The Qnidos Deutsche Health Intelligence study "Enteral Nutrition in France" provides managers of manufacturers and service providers with a comprehensive insight into current and future market events. The focus of the market investigation is on the detailed presentation of the situation of enteral nutrition in the inpatient and outpatient sector. The market shares of selected manufacturers and service providers are also presented.
In addition to a detailed growth forecast for the next three years, the study answers the following questions on enteral nutrition:
How does the French health insurance system work?
How does the reimbursement market work?
How is the market volume distributed among the individual segments (drinking, probe food, medical technology)?
How are the inpatient and outpatient markets developing?
What development have the reimbursement prices been?
The Qnidos Deutsche Health Intelligence study "Enteral Nutrition in France" provides managers of manufacturers and service providers with a comprehensive insight into current and future market events. The focus of the market investigation is on the detailed presentation of the situation of enteral nutrition in the inpatient and outpatient sector. The market shares of selected manufacturers and service providers are also presented.
In addition to a detailed growth forecast for the next three years, the study answers the following questions on enteral nutrition:
How does the French health insurance system work?
How does the reimbursement market work?
How is the market volume distributed among the individual segments (drinking, probe food, medical technology)?
How are the inpatient and outpatient markets developing?
What development have the reimbursement prices been?
